NashBio

Nashville Biosciences is a pioneering brand leveraging real-world clinical, genomic, and imaging data to advance the discovery and development of new, more personalized therapeutics and diagnostics. They offer a range of product offerings, including the Synthetic Control Arm to Boost Clinical Development, Measuring the Impact of New Drug Treatments, Improving Early-Stage Drug Discovery Process, Early Stage Drug Target Prioritization, Disease Risk Modeling, and Pharmacovigilance.

What sets Nashville Biosciences apart is their unique approach, pairing deep scientific and clinical expertise with data-enabled tools to help guide their clients towards their R&D goals. Their offerings leverage the richest and largest de-identified EMR and linked bio-specimen repository in the world, BioVU ®.

In addition to their products and services, Nashville Biosciences also provides medical imaging data across various modalities to support R&D efforts. They are committed to propelling precision medicine R&D for historically underrepresented populations, as evidenced by their sequencing agreement with Amgen. With a focus on improving R&D productivity and uncovering new ways to diagnose and care for diseases more efficiently, Nashville Biosciences is at the forefront of genomics research.